**REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 MARCH 2025** March 2025 and have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102). **----- Start of picture text -----**
About PLANETS
**----- End of picture text -----**
PLANETS Cancer Charity helps patients with pancreatic, liver, colorectal, gastric, oesophageal and neuroendocrine cancer by funding patient support groups, innovative treatments and research. Since 2011 we have raised just over £2.5 million. PLANETS is dedicated to serving the needs of our regional population which extends from Lyme Regis to Bognor Regis and provides specialist cancer services to the four million people who live across Hampshire, Wiltshire, Dorset, the Isle of Wight, the Channel Islands and West Sussex. **----- Start of picture text -----**
Vision
**----- End of picture text -----**
Transforming cancer care in the south through our ‘family' of patients, supporters and healthcare professionals to deliver world leading innovation, research and support for those affected by cancer within the PLANETS community. Our ethos is one of inclusivity, where doctors, nurses, patients, family members, other healthcare workers and supporters all recognise each other’s contributions and work together with a shared vision. In line with our vision and objectives, we will ensure that: - Patients and their families receive outstanding support - The charity continues to support the provision of cutting-edge clinical care and treatment through investment in advanced and innovative treatments - We are accountable for how we spend our income and the impact it makes - We strive for continuous development and improvement of our team and the support and experience we provide - We help drive a change in attitudes amongst health care professionals and the public to generate optimism around PLANETS cancers and their treatment 1 **----- Start of picture text -----**
Our goals
**----- End of picture text -----**
- 1) Improve patient outcomes: Longer survival and a better quality of life through early diagnosis and enhanced treatment conditions. - 2) Better patient experience: Improved support, information communication and facilities for patients. 3) Assist the development of our centres: We can only achieve goals 1 and 2 by facilitating the development of our clinical teams and centres, so we can attract funding for clinical support, diagnosis, therapeutics and research. **----- Start of picture text -----**
Objectives and activities
**----- End of picture text -----**
PLANETS Cancer Charity helps patients with pancreatic, liver, colorectal, gastric, oesophageal and neuroendocrine cancer by funding patient support groups, innovative treatments, and research. **----- Start of picture text -----**
Public benefit
**----- End of picture text -----**
general guidance on public benefit when reviewing the charity's aims and objectives and in planning future activities. The trustees refer to public benefit throughout this report. **----- Start of picture text -----**
ACHIEVEMENT AND PERFORMANCE - Charitable activities
**----- End of picture text -----**
Since our inception in 2011, PLANETS Cancer Charity has grown from a hospital charity fund into a fully independent organisation in 2019. Over the past 14 years, we’ve built a powerful and supportive community of patients, carers and healthcare professionals. Together, we've achieved more than many thought possible. Our Key Achievements Include: ## **Building a Supportive Network** We have established a network of patient support groups and hosted educational conferences across the Wessex region, focusing on pancreatic, colorectal, oesophageal, and neuroendocrine cancers. ## **Pioneering Intra-Operative Radiotherapy (IORT)** radiotherapy machine. This revolutionary technology delivers radiotherapy during surgery to treat advanced cancers. It has already treated over 200 patients (as of December 2022) and is expected to benefit more than 2,000 over its lifespan. The treatment has significantly reduced recurrence rates and led to groundbreaking clinical outcomes published in top international medical journals. 2 ## **Advancing Cancer Research** We have funded full-time PhD and MD researchers in pancreatic and neuroendocrine tumours to work with clinician-scientists at the globally renowned Cancer Immunology Centre at the University of Southampton. ## **Achieving Centre of Excellence Status** In 2016, we helped the Southampton, Portsmouth and Bournemouth/Poole region attain patient care and clinical research. ## **Supporting Innovative Treatments** We funded the introduction of **Hyperthermic Intraperitoneal Chemotherapy (HiPEC)** at University Hospital Southampton—one of the UK’s first centres to offer this treatment, used to target cancers that have spread within the abdomen. ## **Employing a Dedicated Neuroendocrine Tumour Dietitian** tumour patients, helping manage the significant digestive complications associated with these rare cancers. This Dietitian was reappointed through Direct Hospitals after 2 years and now works permanently across the Dorset and Hampshire region. ## **Revolutionising Surgical Planning with 3D Printing** We funded a trial using 3D-printed liver models based on individual patients’ CT scans. These personalised, anatomically precise models enable surgeons to better plan complex operations by visualising tumours and their proximity to vital structures. This innovation made Southampton the first UK centre to use this technology for liver cancer surgery—an initiative that garnered national media attention. ## **Improving Outcomes in Hilar Cholangiocarcinoma Surgery** By converting CT and MRI scans into 3D models, we’re supporting better preoperative planning for hilar cholangiocarcinoma, a bile duct cancer often deemed inoperable until exploratory surgery. These models allow surgeons to assess critical structures ahead of time, reducing the risk of irreversible surgical decisions and improving patient outcomes. 3 ## **Creating a Dedicated Wellbeing Room for Liver Patients** We funded the complete refurbishment of a new wellbeing room on Ward D9 at University Hospital Southampton. The space offers patients a calm environment for rest and private conversations, away from the clinical setting. PLANETS contributed £12,000 towards the facility, which was made possible through a partnership with Taylor Wimpey Southern Counties—our 2023 Charity of the Year—which raised over £20,000. ## **Funding the REMACS Study** We supported the **Reconstruction in Extended Margin Cancer Surgery (REMACS)** study, which investigates patient quality of life and cost-effectiveness following perineal reconstruction in abdominopelvic cancer cases. ## **Supporting a Wide Range of Small but Vital Projects** We continue to invest in numerous smaller initiatives that make a big difference to patient care. These include: Ultrasound machines and radioisotope delivery equipment DAB radios for radiotherapy bunkers - Psychotherapy sessions for patients struggling with a cancer diagnosis Personalised fitness programmes to support cancer recovery experience of patients facing pancreatic, liver, colorectal, oesophageal, and neuroendocrine cancers. 4 ## **This year, we proudly funded the following impactful projects:** ## **Advancing Early Detection of Pancreatic Cancer** - We are supporting ongoing research into pancreatic cancer-associated diabetes, genetic variants, and metabolomic analysis using the UK Biobank cohort. This work aims to develop effective strategies for the early detection of pancreatic cancer—widely regarded as having the poorest survival outcomes among all cancers. ## **Acquisition of a Robotic Ultrasound Probe for the UHS HPB Team** - Ultrasound plays a critical role in hepatopancreatobiliary (HPB) surgery, and its importance is magnified in robotic procedures where tactile feedback is absent. It is essential for mapping lesion margins, assessing proximity to major vascular structures, evaluating liver blood flow, and detecting occult disease. - Unlike traditional laparoscopic ultrasound, robotic ultrasound enables the console surgeon to maintain full control—crucial for precision and patient safety. While UHS has already invested in one robotic HPB ultrasound probe, a second was urgently needed to support multiple cases on the same operating list, as current sterilisation turnaround times are insufficient. With the HPB robotic surgery service set to expand significantly over the next 12–24 months, this investment was both timely and strategic. - **Cancer Coaching sessions -** This year, we were delighted to welcome Alison Bailey, Cancer Coach, to the PLANETS team. Her addition enhances the emotional and practical support we offer to patients and their families. Cancer coaching provides a safe, supportive space for individuals to talk through their current experiences and challenges, while equipping them with tools to set realistic, achievable life goals. These sessions empower people to regain a sense of control during an otherwise uncertain time. The coaching is entirely person-centred and tailored to the specific needs of each participant, ensuring meaningful and individualised support. ## **Improving Postoperative Recovery with Valley Cushions** Following pelvic exenteration surgeries, patients with perineal wounds currently rely on makeshift support such as two pillows, typically introduced around day 10 post-operation. However, this solution often lacks stability and can increase the risk of wound breakdown—an outcome affecting up to 25% of patients, with significant implications for recovery time and morbidity.The Valley Cushion is purpose-designed to redistribute weight and offload pressure from the perineal area, thereby enhancing comfort and reducing the likelihood of wound complications. ## **Equipping Surgical Teams with New Theatre Caps** We have provided new theatre caps to ensure our surgical teams maintain high hygiene standards while benefiting from increased comfort during procedures and improve communication pressured operating theatre settings where new members of the team may not remember everybody’s name/role immediately. ## **Supporting Medical Training** We continue to contribute towards the education and development of healthcare professionals through dedicated funding for medical training initiatives. ## **All of this has brought our local cancer community together.** In line with our charitable goals, all funds we raise are being channelled into new treatments that are directly saving lives, patient support initiatives which change the lives of those with cancer and research projects which may one day help us find new treatments such as immunotherapy for current and future patients. 5 **----- Start of picture text -----**
Year in review – April 2024 to 31 March 2025
**----- End of picture text -----**
The last year has been one of consolidation, where we have been able to establish our funding priorities for the coming years by assessing a range of new projects and reevaluate our fundraising goals, in light of this. Although the overall fundraising climate remains challenging for UK charities due to national and international economic pressures, we have nonetheless been able to exceed our fundraising targets yet again. This has come about through a combination of individual donations and grants, fundraising events and successful grant applications. All of these have been very productive . areas which have reflected positively on the success of our new staffing structure our new projects. We expect that over the next two years our reserve funds will probably reduce as we service these projects. Looking forward the prospects for the economic climate do not look good so we will need to prioritise grant applications and consider how best this may be achieved to ensure that we can continue to service our funding commitments. Fundraising highlights have included our Dawn to Dusk cycle ride which raised over £66,000 and saw more than 50 riders of all levels of experience cycle from Winchester Cathedral to the Bristol Channel during the day. Our annual ball was held at the Grand in Southampton and was it's usual success thanks to the extreme generosity of some of our auction prize donors. We have also had multiple small events including another tandem skydive, The Southsea Alternative Choir music gigs and a golf day. We have been able to fund sessions from a cancer coach over the course of the year partly through successful grant applications. This is a new role which we will be evaluating to assess its long term value, in providing a different type of support for people living with cancer and their close relatives. In general the goal is to help individuals who are struggling with managing the diagnosis come to terms with it and find ways of developing coping strategies . These in turn enable them to feel more in control of their lives and as a result more able to balance the competing pressures that they face and live more rewarding and fruitful lives. The initial feedback is extremely positive and we are looking to continue this over the coming year. Our Cancer Research projects continue to be productive, in particular we are looking to continue funding projects originally initiated by Liver and Pancreas Research and Development Fund also known as LAP R&D. This fund was transferred from Southampton Hospital Charity to PLANETS Cancer charity by mutual agreement in order to continue this project after the LAP R&D Fund founder, my former colleague Professor Mohammed Abu Hilal, moved abroad to work. At present this project is looking at data from the UK National Biobank to look for markers predicting development of pancreatic cancer. Early results are encouraging and we look forward to hearing more from this team. reconstruction following surgery for advanced cancers low in the pelvis. These results have been presented and published during this year and will help guide surgeons in future. A new area that we 6 have started to collaborate on is early research into a new group of potential chemotherapy agents which will work by attacking the mechanisms which allow cancer cells to spread. Normally chemotherapy works by interfering with the way tumour cells grow causing them to slow down or die. The novel approach that we are exploring could have many applications including pancreatic, bowel and neuroendocrine cancers. Our patient support groups have continued to expand into new areas, with the introduction of the first support group in the UK for patients recovering from complex pelvic floor surgery. This was very well attended by patients from across the country as well as those treated locally by our team of experts, led by PLANETS Trustee Professor Alex Mirnezami. Over the course of the year one of our valued trustees Emily Medway asked to stand down and was replaced by Fergus Noble. I am extremely grateful to both for their commitment, help and service. Over the coming year we will look to further refresh and strengthen our Board of Trustees in order to continue to vigorously support our charitable objectives. As always I am extremely grateful to our staff, trustees, patron, ambassadors and many supporters who continue to enable our charity to put the icing on the cake and maintain the strength of cancer care provision, patient support and research within the central South Coast area. ## **Neil Pearce - July 2025** 7 ## **- Media Activity April 2024 to April 2025** Over the course of this period, we recorded 190 items of coverage with an audience reach of 120 to 150 million impressions across national, regional and syndicated (news wire) media coverage. Some of the stories which we have published in the media this year include: **----- Start of picture text -----**
May 2024
**----- End of picture text -----**
PLANETS hailed the decision to make an innovative and targeted radiotherapy treatment available on the NHS for patients with neuroendocrine tumours (NETs) in the liver. We ran a press release urgently requesting a change in NHS commissioning that would allow patients equal access to Selective Internal Radiation Therapy (SIRT) for neuroendocrine tumours (NETs) that have spread to the liver. It is currently only funded for NHS patients with primary liver cancer and colorectal cancer which has spread to the liver – despite the recent publication of NICE guidance which recommends SIRT as a standard treatment option for NET patients. quality of care available across the UK. **----- Start of picture text -----**
June 2024
**----- End of picture text -----**
In June we raised an incredible £66,000 + at our ’Dawn to Dusk’ cycle challenge - £10,000 over target. Jo Green, director of operations and marketing for PLANETS who is a neuroendocrine cancer patient and participated in the 100-mile challenge, said: “We are immensely proud of what our patients, clinicians, supporters and sponsors achieved through our Dawn to Dusk challenge and cannot thank everyone enough – it truly was epic. “We had a total of 54 participants aged from 15 to 74 who all made it through the 100 miles and who all played their part in securing £60,000 for the charity which will prove vital to the work we do for cancer patients. 8 “We all feel extremely fortunate to have shared this amazing experience with so many brilliant people and it really shows what can be achieved when people come together, not just in terms of fundraising but also the friendships and bonds created along the way.” **----- Start of picture text -----**
July 2024
**----- End of picture text -----**
PLANETS called on the government to intervene urgently over the shortage of a drug that can prevent life-threatening digestive problems in thousands of people with a range of medical conditions.. The treatment is often referred to as Creon which is the brand name of a commonly-used type of the drug.PERT is prescribed for patients with pancreatic deficiencies caused by a variety of conditions including pancreatic cancer, pancreatic surgery, cystic fibrosis, chronic pancreatitis and neuroendocrine tumours. Patients who rely on the medication suffer severe abdominal cramps and a particularly unpleasant form of diarrhoea when they are unable to obtain it – typically taking a handful of the tablets with every meal to avoid these symptoms. Lack of adequate PERT leads to malnutrition, with rapid weight loss, fatigue, vitamin and mineral deficiency, susceptibility to infections and, as many of these patients are diabetic, their blood sugars become increasingly difficult to control. The shortage has been caused by a number of factors including supply chain issues across Europe exacerbated by leaving the European Union, the lack of a UK manufacturer and a worldwide increase in demand due to a rise in the number of patients living with the conditions related to it. 9 **----- Start of picture text -----**
August 2024
**----- End of picture text -----**
In August we issues further coverage of our campaign to improve travel insurance cost and cover for cancer patients. **----- Start of picture text -----**
September 2024
**----- End of picture text -----**
In September some of our patients from across the south, their clinicians and family members raised more than £9,500 by leaping from Europe’s largest drop zone 10 **----- Start of picture text -----**
October 2024
**----- End of picture text -----**
We reported that our UHS researchers funded by PLANETS found taking aspirin regularly cuts the risk of developing pancreatic cancer by 40% in people with diabetes – and by 20% in the general population. **----- Start of picture text -----**
February 2025
**----- End of picture text -----**
Research published in the journal Cancers and part-funded by PLANETS found patients with complex cancers of the abdomen and pelvis which were previously deemed inoperable are now surviving longterm thanks to developments in surgical techniques and expertise. 11 **----- Start of picture text -----**
FINANCIAL REVIEW
Financial position
**----- End of picture text -----**
2025 the charity bank balance was £317,055 (plus £85,311, 85,000 and £89,163) in three high interest savings accounts). The charity generated income of £378,022 for the period from 1 April 2024 to 31 March 2025. and Development Projects. **This year, PLANETS Cancer Charity funded several impactful initiatives:** ## **Pancreatic Cancer Research** We supported ongoing studies using UK Biobank data to improve early detection of pancreatic cancer, one of the deadliest cancer types. ## **Robotic Ultrasound Probe for HPB Surgery** We funded a second robotic ultrasound probe for UHS to enhance precision in complex HPB surgeries, supporting the growth of the robotic surgery service. ## **Valley Cushions for Postoperative Recovery** We provided specialist cushions to improve comfort and reduce wound complications in patients recovering from pelvic exenteration surgeries. ## **Theatre Caps for Surgical Teams** We supplied new surgical caps to promote hygiene and comfort in operating theatres. ## **Medical Training Support** - We continued to invest in training and professional development for healthcare staff. **Patient Support -** We also funded numerous patient support days and conferences. The Charity will continue to operate normally for a period of at least 12 months from the date of approval of the financial statements. **----- Start of picture text -----**
FINANCIAL REVIEW - Reserves policy
**----- End of picture text -----**
For **2024/25** the Charity's reserves policy, which is reviewed each year, was to retain an amount of unrestricted reserves which was enough to cover 1 year of governance, management, fundraising and administration. We aim to spend income within 36 months of receipt. Where sums are set aside towards the cost of a project or piece of equipment, we ring fence those sums until enough money is available to meet the full cost of the project. 12 **----- Start of picture text -----**
FUTURE PLANS
**----- End of picture text -----**
Help Us Raise £2 Million to Transform Cancer Care Over the Next Five Years To meet our ambitious goals, we must raise **£2 million** enable us to provide: - **£250,000** for direct patient support - **£500,000** to advance research into PLANETS cancers - **£750,000** for cutting-edge, innovative treatments We are also committed to keeping our administrative costs below 25% of total turnover, ensuring your donations deliver the greatest possible impact. In today’s cost-conscious NHS environment, research and innovation are under threat. At PLANETS, we are determined to ensure that patients across our region—and beyond—continue to receive worldleading care and access to the latest treatments. Your support will help us fund several critical initiatives, including: ## **The REMACS Study** We are co-funding a PhD researcher in this important national study, focused on quality of life and outcome measures following various surgical techniques for advanced pelvic cancers such as recurrent rectal cancer. ## **Predictive Models for Pancreatic Cancer** We're supporting research into genomic and clinical risk factors to predict those most at risk of developing pancreatic cancer. This includes funding laboratory costs for a dedicated PhD researcher using data from cancer patients and the UK Biobank. ## **Upper GI Cancer Network Data Controller (50% funded)** strengthening the quality, consistency, and security of data collection within the Upper GI cancer network. The initiative is 50% funded by PLANETS Charity and reflects our ongoing commitment to advancing both clinical care and research across the region. The project will support the appointment of a dedicated **Data Controller** , who will play a pivotal role in managing cancer data across multiple trusts, ensuring it is collected, stored, and shared in a secure, standardised, and ethically compliant manner. By improving data accuracy and accessibility, this role will directly enhance patient care, clinical decision-making, and outcomes tracking. This is a **collaborative initiative** between **Dorset County Hospital, Portsmouth Hospitals University NHS Trust** , and **University Hospital Southampton** , designed to foster data integration and knowledge-sharing across institutions. Ultimately, the project aims to lay the foundation for a robust, region-wide Upper GI cancer dataset that can inform both local service improvements and national research priorities. 13 **Development and testing of a new drug class in Pancreatic, Liver, and Neuroendocrine cancers.** Cancer remains one of the greatest medical challenges, with spread of the cancer (metastasis) and resistance to drug treatment (chemotherapy resistance) representing two of the main causes of cancer related death. We have previously showed that most cancers activate a key biological process called epithelial-mesenchymal transition (EMT) which leads to cancer spread and drug resistance, and that targeting this pathway can lead to cancer cell death. However, existing drugs that target this pathway have high toxicity. By collaborating with the Chemistry department at the University of Southampton, through a EPSRC research grant, we have now developed four novel compounds targeting this pathway that can kill Neuroendocrine, Hepatocellular and Pancreatic cancer but induce no harm in normal cells ## **Jet Vent Machine** This advanced technology enables prolonged breath-hold techniques (60–90 minutes), significantly expanding the range and complexity of our liver ablation services, allowing us to treat more—and more complex—cases. ## **Da Vinci Robotic Surgery Console** Funding a new Da Vinci surgical console will double the number of PLANETS cancer patients receiving minimally invasive robotic surgery at the regional cancer centre in Southampton. This will also help us establish UHS as a national training hub for robotic cancer surgery. ## **Why It Matters** Each of these projects represents a leap forward in **patient care** , , and **clinical innovation** . But none of it is possible without the generosity of people like you. ## **Join us in shaping the future of cancer care. Together, we can save lives.** 14 **----- Start of picture text -----**
STRUCTURE, GOVERNANCE AND MANAGEMENT - Governing document
**----- End of picture text -----**
The charity is controlled by its governing document, a deed of trust and constitutes an unincorporated charity. PLANETS is a Foundation Charitable Incorporated Organisation (CIO) and is governed in accordance with its constitution. The only members of the CIO shall be those persons who are appointed as Trustees of the CIO, and all persons appointed as Trustees shall be admitted as members. Membership cannot be transferred to anyone else. A member shall cease to be a member immediately that he or she ceases to be a Trustee of the CIO for any reason. **----- Start of picture text -----**
REFERENCE AND ADMINISTRATIVE DETAILS
**----- End of picture text -----**
Registered Charity number - 1175572 Principal address - Milestone Cottage, 113 Havant Rd, Emsworth, Hampshire, PO10 7LG Chairman of trustees - Mr Neil Pearce **----- Start of picture text -----**
Trustees
**----- End of picture text -----**
Dr B Stedman Professor A Mirnezami Dr F Noble Mr C Hoyland Miss V Caine Miss R M H Willrich ## **Independent Examiner** S Mackie, FCA, Morris Crocker, Chartered Accountants Station House, North Street, Havant, Hampshire, PO9 1QU Approved by order of the board of trustees on 31[st] October 2025 and signed on its behalf by: Dr B Stedman - Trustee 15 ## **INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF PLANETS CANCER CHARITY** ## **Independent examiner's report to the trustees of Planets Cancer Charity** I report to the charity trustees on my examination of the accounts of Planets Cancer Charity (the Trust) for the year ended 31 March 2025. ## **Responsibilities and basis of report** As the charity trustees of the Trust you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the Act'). I report in respect of my examination of the Trust's accounts carried out under Section 145 of the Act and in carrying out my examination I have followed all applicable Directions given by the Charity Commission under Section 145(5)(b) of the Act. ## **Independent examiner's statement** Since your charity's gross income exceeded £250,000 your examiner must be a member of a listed body. I can confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Accountants in England and Wales, which is one of the listed bodies. I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect: 1. accounting records were not kept in respect of the Trust as required by Section 130 of the Act; or 2. the accounts do not accord with those records; or 3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination. I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached. S Mackie, FCA Morris Crocker Chartered Accountants Station House North Street Havant Hampshire PO9 1QU Date: ............................................. 11/11/25 16 ## **PLANETS CANCER CHARITY** ## **STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 MARCH 2025** |Unrestricted
funds
Notes
£
**INCOME AND ENDOWMENTS FROM**
Donations and legacies
2
141,221
**Charitable activities**
5
Charitable activities
124
Other trading activities
3
103,958
Investment income
4
4,495
**Total**
249,798
**EXPENDITURE ON**
Raising funds
6
37,693
**Charitable activities**
7
Charitable activities
179,866
**Total**
217,559
**NET INCOME**
32,239
**RECONCILIATION OF FUNDS**
Total funds brought forward
458,373
**TOTAL FUNDS CARRIED FORWARD**
490,612|Restricted
funds
£
128,224
-
-
-
128,224
-
25,194
25,194
103,030
5,130
108,160|2025
Total
funds
£
269,445
124
103,958
4,495
378,022
37,693
205,060
242,753
135,269
463,503
598,772|2024
Total
funds
£
363,955
80
55,852
9
419,896
28,739
208,025
236,764
183,132
280,371
463,503| |---|---|---|---| The notes form part of these financial statements 17 ## **PLANETS CANCER CHARITY** ## **BALANCE SHEET 31 MARCH 2025** |Notes
**CURRENT ASSETS**
Stocks
12
Debtors
13
Cash at bank
**CREDITORS**
Amounts falling due within one year
14
**NET CURRENT ASSETS**
**TOTAL ASSETS LESS CURRENT**
**LIABILITIES**
**NET ASSETS**
**FUNDS**
16
Unrestricted funds
Restricted funds
**TOTAL FUNDS**|2025
£
3,558
21,024
576,550
601,132
(2,360)
598,772
598,772
598,772
490,612
108,160
598,772|2024
£
4,339
-
460,617
464,956
(1,453)
463,503
463,503
463,503
458,373
5,130
463,503| |---|---|---| The financial statements were approved by the Board of Trustees and authorised for issue on 10 November 2025 and were signed on its behalf by: B Stedman - Trustee The notes form part of these financial statements 18 **PLANETS CANCER CHARITY** ## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025** ## **1. ACCOUNTING POLICIES** ## **Basis of preparing the financial statements** The financial statements of the charity, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Charities Act 2011. The financial statements have been prepared under the historical cost convention. The trustees consider that there are no material uncertainties about the Charity's ability to continue as a going concern. ## **Income** All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably. ## **Expenditure** Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources. ## **Stocks** Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items. ## **Taxation** The charity is exempt from tax on its charitable activities. ## **Fund accounting** Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees. Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes. Further explanation of the nature and purpose of each fund is included in the notes to the financial statements. ## **Hire purchase and leasing commitments** Rentals paid under operating leases are charged to the Statement of Financial Activities on a straight line basis over the period of the lease. ## **Financial instruments** The charity only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities like trade and other accounts receivable and payable investments in stocks and shares. The measurement basis used for these instruments is detailed below. ## **Debtors and cash at bank** Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due. Cash at bank and in hand included cash held on deposit or in a current account. 19 ## **PLANETS CANCER CHARITY** ## **NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025** ## **1. ACCOUNTING POLICIES - continued** ## **Financial instruments** ## **Creditors and provisions** Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due. ## **2. DONATIONS AND LEGACIES** |Donations
Legacies
Ring-fenced Donations - R&D
Ring fenced donations - Grange /R&D
Ring-fenced Donations - Robotics Project
Ring-fenced Donations - UGI Data Project
**3.**
**OTHER TRADING ACTIVITIES**
Fundraising events
**4.**
**INVESTMENT INCOME**
Deposit account interest
All investment income is derived from assets held in the United Kingdom.
**5.**
**INCOME FROM CHARITABLE ACTIVITIES**
Activity
Merchandising
Charitable activities|2025
£
159,421
-
23,024
-
25,000
62,000
269,445
2025
£
103,958
2025
£
4,495
2025
£
124|2024
£
129,168
33,949
838
200,000
-
-
363,955
2024
£
55,852
2024
£
9
2024
£
80| |---|---|---| |||| 20 ## **PLANETS CANCER CHARITY** ## **NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025** ## **6. RAISING FUNDS** ## **Raising donations and legacies** |Fundraising expenditure
**7.**
**CHARITABLE ACTIVITIES COSTS**
Charitable activities
**8.**
**SUPPORT COSTS**
Management
£
Charitable activities
8,120|2025
£
37,693
Support
Direct
costs (see
Costs
note 8)
£
£
192,045
13,015
Governance
Finance
costs
£
£
276
4,619|2024
£
28,739
Totals
£
205,060|2024
£
28,739| |---|---|---|---| |||Totals
£
13,015|| Support costs, included in the above, are as follows: ## **Management** |**Management**||| |---|---|---| ||2025|2024| ||Charitable|Total| ||activities|activities| ||£|£| |Computer costs|6,991|5,356| |Training costs|-|945| |Postage and stationery|1,129|940| ||8,120|7,241| |**Finance**||| ||2025|2024| ||Charitable|Total| ||activities|activities| ||£|£| |Bank charges|276|168| |**Governance costs**||| ||2025|2024| ||Charitable|Total| ||activities|activities| ||£|£| |Professional fee|1,394|1,051| |Trustee meeting expenses|1,104|957| |Accountancy|1,509|1,386| |Payroll|612|487| ||4,619|3,881| 21 **PLANETS CANCER CHARITY** ## **NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025** ## **9. TRUSTEES' REMUNERATION AND BENEFITS** There were no trustees' remuneration or other benefits for the year ended 31 March 2025 nor for the year ended 31 March 2024. ## **Trustees' expenses** During the year no trustees (2024: none) were reimbursed out of pocket expenses totalling £nil (2024: £nil). ## **10. STAFF COSTS** No employees received emoluments in excess of £60,000. The key management personnel of the charity comprise the Operations Director, Chief Executive and Fundraising Officer with remuneration totalling £119,617 for 2025 (2024: £121,704). ## **11. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES** |Unrestricted
funds
£
**INCOME AND ENDOWMENTS FROM**
Donations and legacies
363,117
**Charitable activities**
Charitable activities
80
Other trading activities
55,852
Investment income
9
**Total**
419,058
**EXPENDITURE ON**
Raising funds
28,739
**Charitable activities**
Charitable activities
195,215
**Total**
223,954
**NET INCOME/(EXPENDITURE)**
195,104
**RECONCILIATION OF FUNDS**
Total funds brought forward
263,269
**TOTAL FUNDS CARRIED FORWARD**
458,373|Restricted
funds
£
838
-
-
-
838
-
12,810
12,810
(11,972)
17,102
5,130|Total
funds
£
363,955
80
55,852
9
419,896
28,739
208,025
236,764
183,132
280,371
463,503| |---|---|---| 22 **PLANETS CANCER CHARITY** ## **NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025** |**12.**
**STOCKS**
Stocks
**13.**
**DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**
Trade debtors
**14.**
**CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**
Other creditors
**15.**
**ANALYSIS OF NET ASSETS BETWEEN FUNDS**
Unrestricted
Restricted
funds
funds
£
£
Current assets
492,972
108,160
Current liabilities
(2,360)
-
490,612
108,160
**16.**
**MOVEMENT IN FUNDS**
At 1.4.24
£
**Unrestricted funds**
General fund
258,373
Grange donation
200,000
458,373
**Restricted funds**
R&D fund
5,130
Robotics Project
-
UGI Data Project
-
Patient Support
-
5,130
**TOTAL FUNDS**
463,503|2025
£
3,558
2025
£
21,024
2025
£
2,360
2025
Total
funds
£
601,132
(2,360)
598,772
Net
movement
in funds
£
32,239
-
32,239
(2,170)
25,000
62,000
18,200
103,030
135,269|2024
£
4,339
2024
£
-
2024
£
1,453
2024
Total
funds
£
464,956
(1,453)
463,503
At
31.3.25
£
290,612
200,000
490,612
2,960
25,000
62,000
18,200
108,160
598,772| |---|---|---| 23 ## **PLANETS CANCER CHARITY** ## **NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025** ## **16. MOVEMENT IN FUNDS - continued** Net movement in funds, included in the above are as follows: |**Unrestricted funds**
General fund
**Restricted funds**
R&D fund
Robotics Project
UGI Data Project
Patient Support
**TOTAL FUNDS**|Incoming
resources
£
249,798
23,024
25,000
62,000
18,200
128,224
378,022|Resources
Movement
expended
in funds
£
£
(217,559)
32,239
(25,194)
(2,170)
-
25,000
-
62,000
-
18,200
(25,194)
103,030
(242,753)
135,269| |---|---|---| ## **Comparatives for movement in funds** |**Unrestricted funds**
General fund
Grange donation
**Restricted funds**
R&D fund
**TOTAL FUNDS**|At 1.4.23
£
263,269
-
263,269
17,102
280,371|Net
movement
in funds
£
(4,896)
200,000
195,104
(11,972)
183,132|At
31.3.24
£
258,373
200,000
458,373
5,130
463,503| |---|---|---|---| Comparative net movement in funds, included in the above are as follows: |**Unrestricted funds**
General fund
Grange donation
**Restricted funds**
R&D fund
**TOTAL FUNDS**|Incoming
resources
£
219,058
200,000
419,058
838
419,896|Resources
Movement
expended
in funds
£
£
(223,954)
(4,896)
-
200,000
(223,954)
195,104
(12,810)
(11,972)
(236,764)
183,132| |---|---|---| REMACS R&D - reconstruction in extended margin cancer surgery (REMACS) pancreatic cancer research and development and model trial. 24 **PLANETS CANCER CHARITY** ## **NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025** ## **16. MOVEMENT IN FUNDS - continued** Grange donation - Monies donated to be put towards suggested items by the donor but with ultimate discretion as to amounts, items and timing left to the trustees to maximise the donation. Robotics Project - The project proposed is the acquisition of a new Da Vinci XI robot platform, to join the existing robotic fleet of 1 Da Vinci X (older model), 1 Da Vinci XI (the same as this one) and 1 CMR Robot. The current Da Vinci platforms are nearing 100% utilisation amongst colorectal, thoracic surgery, HPB surgery, Upper GI Surgery and Urology. This means that there are many patients in these specialities (approximately the same number as are currently being treated with robotic surgery) that could benefit from the enhanced clinical outcomes that robotic surgery can offer, particularly for those patients who can currently only be offered open surgery. UGI Data Project - To enable dedicated and consistent, accurate, timely and secure data acquisition from clinical and basic/translational science sources building upon the existing successful infrastructure in the ITRG. We will extend data acquisition from UHS/UoS to include Portsmouth and Bournemouth patients. Patient Support - Patient support groups for our patients covering each cancer type that PLANETS manage. This is covering patients in the Dorset and Hampshire areas ( and beyond ) and includes Cancer coaching , conferences and coffee mornings. ## **17. RELATED PARTY DISCLOSURES** There were no related party transactions for the year ended 31 March 2025. 25